Research Paper Volume 12, Issue 1 pp 784—807

CCL14 is a prognostic biomarker and correlates with immune infiltrates in hepatocellular carcinoma

Figure 2. Kaplan-Meier survival curve analysis of the prognostic significance of high and low expression of CCL14 in different types of human cancers using the Kaplan-Meier plotter database (A-S). (AD) High CCL14 expression was correlated with better OS, PFS, RFS and DSS in HCC cohorts (n=364, n=370, n=316, n=362). (EH) Survival curves of OS, PPS, RFS and DMFS in the breast cancer cohort (n=1,404, n=414, n=3,915). (IK) OS, PS and DFS survival curves of gastric cancer. High CCL14 expression was correlated with poor OS and PS (n = 876, n = 499, n=641). (L, M) OS and RFS survival curves of ductal adenocarcinoma (n = 69, n = 177). (NP) OS, PPS and FP survival curves of lung cancer (n = 1,926, n = 344, n=982). (QS) OS, PFS and PPS survival curves of ovarian cancer (n = 1,656, n = 1,435, n=782). OS, overall survival; PFS, progression-free survival; RFS, relapse-free survival; DSS, disease-specific survival. DMFS, distant metastasis-free survival; PPS, post progression survival; FP, first progression.